ECO Animal Health Group announced on Monday that its subsidiary, ECO Animal Health do Brasil, has received a marketing authorisation from the Brazilian Ministry of Agriculture, Livestock and Supply for the use of Aivlosin 625 mg/g water soluble granules in swine.
The AIM-traded firm said its patented antimicrobial is used under veterinary prescription for the treatment of a variety of economically important respiratory and enteric diseases in poultry and pigs.
It said the approved formulation of Aivlosin will be marketed for the treatment of ileitis, or porcine proliferative enteropathy, which is a gut disease of swine.
ECO claimed that, with global concerns about the use of antibiotics in production animals, the new treatment with its low therapeutic dose rate and short treatment duration meets antimicrobial stewardship guidelines.
“This approval from the Brazilian MAPA is very important in the development of Aivlosin for swine globally,” said chairman Peter Lawrence.
“Brazil is one of the world’s leading producers and exporters of pork and this new formulation will enhance our ability to offer an expanded range of valuable therapeutic tools to swine producers for both the domestic and export markets.”